Commentary
Recently, a consensus recommended ‘metabolic (dysfunction) associated fatty liver disease’ as a more appropriate name to describe fatty liver disease associated with metabolic dysfunction (MAFLD). This single-letter change in the NAFLD acronym suggests that the old acronyms should be abandoned.
In this viewpoint, Y. Yilmaz, C. D. Byrne and G. Musso discuss the reasons and relevance of this semantic modification. This modification should encourage increased disease awareness among policymakers and stimulate public and private investments leading to more effective therapy development.
